

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		Application Number	10/001,221
		Filing Date	October 30, 2001
		First Named Inventor	Schall, Thomas J.
		Art Unit	1642
		Examiner Name	Canella, Karen A.
Total Number of Pages in This Submission		Attorney Docket Number	019934-004100US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of thirty-one (31) cited references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Aussenhus Reg. No. 42,271
Signature	
Date	01-28-04

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Nicole M. Wartell		
Signature		Date	1/28/04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 019934-004100US


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



On JAN 28, 2004

TOWNSEND and TOWNSEND and CREW LLP

By:

  
Nicole M. Wartell

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Thomas J. Schall

Application No.: 10/001,221

Filed: October 30, 2001

For: METHODS AND COMPOSITIONS  
FOR INDUCING AN IMMUNE  
RESPONSE

Examiner: Canella, Karen A.

Art Unit: 1642

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
60126179 v1




<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/001,221	
			Filing Date	October 30, 2001	
			First Named Inventor	Schall, Thomas J.	
			Art Unit	1642	
Examiner Name	Canella, Karen A.				
Attorney Docket Number	019934-004100US				
Sheet	1	of	3		

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-5,141,867	08-25-1992	Ivanoff et al.	
	A2	US-5,705,151	01-06-1998	Dow et al.	
	A3	US-5,837,247	11-17-1998	Oppenheim et al.	
	A4	US-5,935,568	08-10-1999	Dow et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> ( <i>if known</i> )				
	B1	PCT	WO 94/28916	A1	12-22-1994	British Biotech Pharmaceuticals Limited		<input type="checkbox"/>
	B2	PCT	WO 96/11279	A2	04-18-1996	Government of the United States - Department of Health and Human Services		<input type="checkbox"/>
	B3	PCT	WO 96/36366	A1	11-21-1996	National Jewish Center for Immunology and Respiratory Medicine		<input type="checkbox"/>
	B4	PCT	WO 97/19696	A1	06-05-1997	Lusso, Paolo; Gallo, Robert C.; Cocchi, Fiorenza; DeVico, Anthony; Garzino-Demo, Alfredo		<input type="checkbox"/>
	B5	PCT	WO 98/15285	A1	04-16-1998	The Wistar Institute of Anatomy and Biology		<input type="checkbox"/>
	B6	PCT	WO 99/43839	A1	09-02-1999	Trustee of the University of Pennsylvania		<input type="checkbox"/>
	B7	PCT	WO 99/53960	A2	10-28-1999	Chiron Corp.		<input type="checkbox"/>
	B8	PCT	WO 00/22124	A2	04-20-2000	Canji, Inc.		<input type="checkbox"/>
	B9	PCT	WO 01/80882	A3	11-01-2001	ChemoCentryx, Inc.		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60126179 v1



<div>Substitute for form 1449B/PTO</div> <div><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></div> <div>(use as many sheets as necessary)</div>				<b>Complete if Known</b>	
				Application Number	10/001,221
				Filing Date	October 30, 2001
				First Named Inventor	Schall, Thomas J.
				Art Unit	1642
				Examiner Name	Canella, Karen A.
Sheet	2	of	3	Attorney Docket Number	019934-004100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	BANCHEREAU, JACQUES and RALPH M. STEINMAN; Dendritic cells and the control of immunity; Nature; 19 March, 1998; pp. 245-252; Vol. 392	
	C2	CAUX, CHRISTOPHE, et al.; Developmental Pathways of Human Myeloid Dendritic Cells; Dendritic Cells: Biology and Clinical Applications; 1999; pp. 63-92 (chapter 5); Academic Press	
	C3	ChemoTx Disposable; Neuro Probe website; Products (1 page) and Protocols (2 pages); Wednesday, April 19, 2000; <a href="http://www.neuroprobe">http://www.neuroprobe</a>	
	C4	CHOW, YEN-HUNG, et al.; Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes; <i>The Journal of Immunology</i> ; 1998; pp. 1320-1329; Vol 160	
	C5	DILLOO, DAGMAR, et al.; Combined chemokine and cytokine gene transfer enhances antitumor immunity; <i>Nature Medicine</i> ; October 1996; pp. 1090-1095; Vol. 2, No. 10	
	C6	ENG, VICKI M., et al.; The Stimulatory Effects of interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon $\gamma$ In Vivo; <i>J. Exp. Med.</i> ; May 1995; pp. 1893-1898; Vol. 181	
	C7	EO, SEONG KUG, et al.; Modulation of Immunity against Herpes Simplex Virus Infection via Mucosal Genetic Transfer of Plasmid DNA Encoding Chemokines; <i>Journal of Virology</i> ; January 2001; pp. 569-578; Vol. 75, No. 2	
	C8	GenBank Accession No. P27784, August 1, 1992	
	C9	KHUDYAKOV, YU E.; et al. Linear B-Cell Epitopes of the NS3-NS4-NS5 Proteins of the Hepatitis C. Virus as Modeled with Synthetic Peptides; <i>Virology</i> ; 1995; pp. 666-672; Vol 206	
	C10	LILJEQVIST, SISSELA & STÅHL, "Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines" <i>Journal of Biotechnology</i> , 1999, pp. 1-33, Vol. 73, Elsevier.	
	C11	MOLDOVEANU, ZINA, et al.; Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins; <i>Vaccine</i> ; 1995; pp. 1013-1022; Vol. 13, No. 11	
	C12	ORANGE, JORDAN S.; et al.; Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids; <i>J. Exp. Med.</i> ; March 1995; pp. 901-914; Vol. 181	
	C13	R & D Systems 2000 Catalog; front and back cover, Contents in Brief, Ordering Information, (page i) Contact Information (page ii), Cytokines & Related Molecules (p. 93-94 and 162), Antibodies (p. 163-164 and 291)	
	C14	RAMSHAW, IAN; et al.; Expression of Cytokines by Recombinant Vaccinia Viruses: A Model for Studying Cytokines in Virus Infections <i>in vivo</i> ; <i>Immunological Reviews</i> ; 1992; pp. 157-182; No. 127	
	C15	TSUJI, T., et al.; HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine; <i>Immunology</i> ; 1997; pp. 1-6; Vol. 90	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<div>Substitute for form 1449B/PTO</div> <div><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></div> <div>(use as many sheets as necessary)</div>				<b>Complete if Known</b>	
				Application Number	10/001,221
				Filing Date	October 30, 2001
				First Named Inventor	Schall, Thomas J.
				Art Unit	1642
				Examiner Name	Canella, Karen A.
Sheet	3	of	3	Attorney Docket Number	019934-004100US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C16	WELLS, JAMES "Additivity of Mutational Effects in Proteins" <i>Biochemistry</i> , September 18, 1990; p. 8509-8517, Vol. 29, No. 37.		
	C17	WU, GEORGE Y., et al.; Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System; <i>The Journal of Biological Chemistry</i> ; 1987; pp. 4429-4432; Vol. 262, No. 10		
	C18	XIANG, ZHIQUAN, et al.; Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines; <i>Immunity</i> ; February 1995; pp. 129-135; Vol. 2		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.